Unity Biotechnology, Inc.

Equities

UBX

US91381U2006

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-01 pm EST 5-day change 1st Jan Change
1.8 USD -1.64% Intraday chart for Unity Biotechnology, Inc. 0.00% -6.74%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Unity Biotechnology, Inc. Announces New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-Lasting, Disease-Modifying Intervention in Vision Loss CI
Unity Biotechnology, Inc. Doses First Patients in Phase 2 Aspire Study of Ubx1325 in DME CI
North American Morning Briefing : Stocks Futures -2- DJ
Wedbush Upgrades Unity Biotechnology to Outperform From Neutral, Says Remains in Execution Mode With Advancement of UBX1325; Raises PT to $4 From $2 MT
Unity Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Sector Update: Health Care Stocks Rising Late Afternoon MT
Sector Update: Health Care MT
Unity Biotechnology Agrees to Exercise Warrants for $4.38 Million in Gross Proceeds; Shares Fall MT
UNITY Biotechnology, Inc. Announces 48-Week Results from Phase 2 Envision Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration CI
Unity Biotechnology, Inc. enters into A Loan and Security Agreement CI
Unity Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
Wedbush Downgrades Unity Biotechnology to Neutral From Outperform, Notes Limited Cash Runway, Lack of Other Near-Term Value-Driving Catalysts; Trims PT to $2 From $3 MT
Unity Biotechnology, Inc. Announces Design of Phase 2B Aspire Study Evaluating Ubx1325 in Diabetic Macular Edema CI
Roth MKM Initiates Unity Biotechnology at Buy With $10 Price Target MT
Citigroup Adjusts Price Target on Unity Biotechnology to $6 From $5, Maintains Buy Rating MT
Unity Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Wedbush Trims Unity Biotechnology's Price Target to $3 From $5 After Model Adjustments, Keeps Outperform Rating MT
Transcript : Unity Biotechnology, Inc. - Special Call
Unity Biotechnology, Inc. Announces Positive 48-Week Results from Phase 2 Bold Study of UBX1325 in Patients with Diabetic Macular Edema CI
Unity Biotechnology, Inc. Announces Resignation of Jamie Dananberg as Chief Medical Officer, Effective April 30, 2023 CI
Citigroup Adjusts Price Target on Unity Biotechnology to $5 From $15, Maintains Buy Rating MT
Wedbush Cuts Unity Biotechnology's PT to $5 From $35 After UBX1325 Study for Wet Age-Related Macular Degeneration Failed to Meet Non-Inferiority Threshold, Keeps Outperform Rating MT
Top Midday Decliners MT
Unity Biotechnology's Study of UBX1325 for Wet Age-Related Macular Degeneration Failed to Meet Non-Inferiority Threshold MT
Chart Unity Biotechnology, Inc.
More charts
Unity Biotechnology, Inc. is engaged in developing therapeutics to slow, halt, or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells. The Company is also focused on advancing senolytic programs primarily in ophthalmologic disorders. It is also focused on advancing other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/vascular endothelial growth factor (VEGF) bispecific to treat vascular eye disease. The Company's UBX1325 and UBX1967 are designed to inhibit the function of proteins that senescent cells rely on for survival. UBX1325 is an advanced drug candidate for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration, (AMD), and diabetic retinopathy (DR). Its UBX2050 is an investigational, fully human anti-Tie2 agonist monoclonal antibody.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.8 USD
Average target price
6.667 USD
Spread / Average Target
+270.37%
Consensus
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW